Tom3 schreef op 22 juni 2020 22:48:
Dit leek me vandaag een trigger voor Arrowhead:
Holden (schreef op Yahoo):
The PPA (Promising Pathway Act) is a HUGE boost to ARWR and this is a minor blip in the stock price. The Golttleib construct was a huge front end boost through p2. The PPA appears to cover the back end p3 development/commercialization process. FDA still appears to have control of approvals but the protocol, much in the same way FDA now handles p1-p2, allows p3 to be submitted for approval (I assume with a full p1-p2 data package) in advance of the actual trial. Theoretically a company could file, conduct the trial and receive labeling approval in one forward motion. Explains why Trump has mentioned this at virtually every rally speech he has given...~"Lower drug prices." Big part of his platform, although underappreciated (Assuming this legislation gets passed). P.S. Anyone notice where Gallagher is from?
All this other XBI rebalancing, CF research funding, etc...are noise relative to this proposed legislation...IMO.